ATE292476T1 - Ein medikament,das hgf gen enthält - Google Patents

Ein medikament,das hgf gen enthält

Info

Publication number
ATE292476T1
ATE292476T1 AT96927886T AT96927886T ATE292476T1 AT E292476 T1 ATE292476 T1 AT E292476T1 AT 96927886 T AT96927886 T AT 96927886T AT 96927886 T AT96927886 T AT 96927886T AT E292476 T1 ATE292476 T1 AT E292476T1
Authority
AT
Austria
Prior art keywords
hgf gene
medication containing
containing hgf
medicament
present
Prior art date
Application number
AT96927886T
Other languages
English (en)
Inventor
Ryuichi Morishita
Toshio Ogihara
Toshikazu Nakamura
Tetsuya Tomita
Takahiro Ochi
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE292476T1 publication Critical patent/ATE292476T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
AT96927886T 1995-08-29 1996-08-22 Ein medikament,das hgf gen enthält ATE292476T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP24547595 1995-08-29
JP5846796 1996-02-20
PCT/JP1996/002359 WO1997007824A1 (en) 1995-08-29 1996-08-22 Medicine comprising hgf gene

Publications (1)

Publication Number Publication Date
ATE292476T1 true ATE292476T1 (de) 2005-04-15

Family

ID=26399523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96927886T ATE292476T1 (de) 1995-08-29 1996-08-22 Ein medikament,das hgf gen enthält

Country Status (13)

Country Link
US (4) US6248722B1 (de)
EP (1) EP0847757B1 (de)
JP (1) JP3431633B2 (de)
KR (2) KR100725199B1 (de)
CN (1) CN100478033C (de)
AT (1) ATE292476T1 (de)
AU (1) AU6754496A (de)
CA (1) CA2230819C (de)
DE (1) DE69634567T2 (de)
ES (1) ES2240999T3 (de)
NZ (1) NZ315769A (de)
PT (1) PT847757E (de)
WO (1) WO1997007824A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756358B2 (en) * 1994-08-19 2004-06-29 Sumitomo Pharmaceuticals Co., Ltd. Therapeutic agent for cartilaginous diseases
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
US6775574B1 (en) * 1997-11-07 2004-08-10 Medtronic, Inc. Method and system for myocardial infarction repair
WO1999048537A1 (en) * 1998-03-26 1999-09-30 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
EP1210046A4 (de) * 1999-06-22 2007-05-02 Res Dev Foundation Verbesserter wundverband zur verstärkung der wundheilung
EP1132098B1 (de) * 1999-09-21 2010-05-26 AnGes MG, Inc. Gentherapie für zerebrale gefässerkrankungen
KR20010093804A (ko) * 1999-10-08 2001-10-29 무라야마 마사노리 심근증 유전자 치료
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
WO2001093899A1 (en) * 2000-06-02 2001-12-13 Hiroshi Okamoto PANCREATIC LANGERHANS β CELL PROLIFERATION PROMOTER AND APOPTOSIS INHIBITOR, AND SCREENING OF CANDIDATE COMPOUNDS FOR THE E DRUGS
EP1320384B1 (de) 2000-08-28 2007-10-10 Damavand Wound AB Die synergistischen wirkungen von hgf und antibakterieller behandlung
JP4554883B2 (ja) * 2000-10-04 2010-09-29 協和発酵キリン株式会社 脂質膜による微粒子の被覆方法
CA2446946A1 (en) 2001-05-09 2002-11-14 Anges Mg, Inc. Gene transfer of angiogenic factor for skin disease
AU2002349583B2 (en) 2001-11-28 2007-11-22 Anges Mg, Inc. Genetic remedies for neurodegenerative diseases
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
DE60332748D1 (de) * 2002-10-02 2010-07-08 Anges Mg Inc Arzneimittel gegen hörfunktionsstörungen
EP1613742A2 (de) * 2003-04-08 2006-01-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Stammzellen mit erhöhter empfindlichkeit gegenüber einem chemoattraktanten sowie verfahren zur erzeugung und verwendung davon
US20050026830A1 (en) * 2003-05-14 2005-02-03 Yasushi Kawaguchi Compositions and methods for treating fibrosis
CA2541603A1 (en) * 2003-10-14 2005-04-21 Kringle Pharma Inc. Agent for improving mental disorders
MX2007001064A (es) * 2004-07-26 2007-04-12 Genentech Inc Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
US20090012498A1 (en) * 2004-10-29 2009-01-08 Yoshiki Sawa Gene therapy for treatment of heart failure
US20110230407A1 (en) * 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
US20110160132A1 (en) * 2005-07-28 2011-06-30 Anges Mg, Inc. Lymphangiogenesis-promoting agents
CN101563097A (zh) * 2005-11-14 2009-10-21 企业合伙人风险资本公司 用于组织损伤的干细胞生长因子疗法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
JP5579164B2 (ja) * 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
CN102149379A (zh) 2008-07-10 2011-08-10 安吉翁生物医药有限公司 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
CN102573924A (zh) 2009-08-31 2012-07-11 福田惠一 血管生成疗法用医药组合物
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
KR101567954B1 (ko) 2013-11-25 2015-11-11 인하대학교 산학협력단 Hgf 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
KR20210027493A (ko) 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물
EP3927702A4 (de) 2019-04-11 2022-05-11 Angion Biomedica Corp. Feste formen von (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazol

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130773C (de) * 1964-04-09
US3560394A (en) * 1964-04-09 1971-02-02 Dow Corning Extracoordinate silicon complexes containing a cyclic anhydride of a polycarboxylic organic acid
BE754961A (fr) * 1969-08-19 1971-02-18 Dow Corning Complexes de silicium pentacoordine d'acides alpha hydroxycarboxylique
US3679630A (en) * 1970-12-11 1972-07-25 Dow Chemical Co Curable compositions comprising a polyepoxide,a polyisocyanato silane and a catalyst therefor
US4171420A (en) * 1974-06-21 1979-10-16 The Dow Chemical Company Latent catalysts for promoting reaction of epoxides with phenols and/or carboxylic acids
EP0452457B1 (de) * 1989-11-03 1997-08-20 Vanderbilt University Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
DE69133492T2 (de) 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
DE4018818C2 (de) * 1990-06-12 1994-03-24 J Dr Med Reinhardt Schläger, insbesondere Tennis- oder Squashschläger
KR950000091B1 (ko) * 1990-06-20 1995-01-09 후지쓰 가부시끼가이샤 위상 천이기가 있는 레티클과 그 제조방법 및 수정방법
EP0571387B1 (de) 1990-09-14 2003-12-17 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Ein nicht-mitogener kompetitiver hgf-antagonist
JP3200609B2 (ja) 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
CA2055811A1 (en) 1991-01-11 1992-07-12 Ross R. Muth Sterilization of growth factors
JP3394982B2 (ja) 1991-11-07 2003-04-07 敏一 中村 ガン療法用副作用防止剤
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
CA2144081C (en) 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
AU1049895A (en) 1993-11-05 1995-05-23 New York University Methods relating to ir-95
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
SG73590A1 (en) * 1997-12-03 2000-06-20 Sumitomo Bakelite Co Latent catalyst thermosetting resin composition comprising the catalyst epoxy resin molding material comprising the catalyst and semiconductor device
EP1132098B1 (de) * 1999-09-21 2010-05-26 AnGes MG, Inc. Gentherapie für zerebrale gefässerkrankungen
KR20010093804A (ko) * 1999-10-08 2001-10-29 무라야마 마사노리 심근증 유전자 치료
EP1238088A2 (de) * 1999-12-08 2002-09-11 Genoptera, LLC Ziele für insektizide und verfahren zu deren verwendung

Also Published As

Publication number Publication date
US20040220126A1 (en) 2004-11-04
ES2240999T3 (es) 2005-10-16
KR100725199B1 (ko) 2007-08-16
KR20040097246A (ko) 2004-11-17
PT847757E (pt) 2005-06-30
EP0847757A1 (de) 1998-06-17
CN1198675A (zh) 1998-11-11
US20090004260A1 (en) 2009-01-01
EP0847757A4 (de) 2000-04-12
US7285540B2 (en) 2007-10-23
KR19990044279A (ko) 1999-06-25
WO1997007824A1 (en) 1997-03-06
CA2230819A1 (en) 1997-03-06
EP0847757B1 (de) 2005-04-06
AU6754496A (en) 1997-03-19
NZ315769A (en) 1999-05-28
CA2230819C (en) 2009-04-14
DE69634567T2 (de) 2006-02-16
DE69634567D1 (de) 2005-05-12
US20040105882A1 (en) 2004-06-03
JP3431633B2 (ja) 2003-07-28
KR100765687B1 (ko) 2007-10-11
US6248722B1 (en) 2001-06-19
CN100478033C (zh) 2009-04-15

Similar Documents

Publication Publication Date Title
ATE292476T1 (de) Ein medikament,das hgf gen enthält
DE3884386D1 (de) Farbkorrektur für eingebettete prismen und farbprojektionssystem, das solche prismen enthält.
FI960219A7 (fi) Letkukatetri
DE68922176D1 (de) Doppelblick-Arthroskop.
DE68916693D1 (de) Molekular-Diagnose von Alzheimer-Krankheit.
ATE199906T1 (de) Phosphonat-nukleotid ester-derivate
DE3884099D1 (de) Farbeanzeige.
FR2676256B1 (fr) Unite d'entrainement pour ventilateur double.
FR2680619B1 (fr) Predicteur d'image.
FI912348L (fi) Stabiliserad fgf sammansaettning.
EP0596729A3 (de) Virtuelle Bildinstrumentenanzeige.
DE3888530D1 (de) 3'-Azido-2',3'-dideoxynucleosid-5'-phosphonate.
DE3870959D1 (de) 2-difluormethoxy-1,1,1,2-tetrafluoraethan als anaesthetikum.
FI923680L (fi) Foerfarande foer framstaellning av (2r,3r) cis-b-fenylglysidinsyra
FR2714772B3 (fr) Perfectionnements apportés à des batteries d'alimentation.
DE69112449D1 (de) Endoskop.
FI941149L (fi) 2,4-diamino-3-hydroksikarboksyylihapon johdannaisia
DE3880069D1 (de) Klinkenfeld mit geteilter frontplatte.
FR2697727B3 (fr) Chaussure d'athlétisme.
NO954147D0 (no) Forbedringer vedrörende pasientheiser
EP0661503A3 (de) Befeuchter.
FR2709510B1 (fr) Monte voitures à double plateforme.
FR2703496B1 (fr) Panneau d'affichage multimessages.
FI923528L (fi) Terapeutiska aemnen.
IT9048244A0 (it) Composizione farmaceutica ad effetto cicatrizzante.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0847757

Country of ref document: EP